Literature DB >> 15156173

Oncogenic potential of the RUNX gene family: 'overview'.

Yoshiaki Ito1.   

Abstract

Runt-related (RUNX) gene family is composed of three members, RUNX1/AML1, RUNX2 and RUNX3, and encodes the DNA-binding (alpha) subunits of the Runt domain transcription factor polyomavirus enhancer-binding protein 2 (PEBP2)/core-binding factor (CBF), which is a heterodimeric transcription factor. RUNX1 is most frequently involved in human acute leukemia. RUNX2 shows oncogenic potential in mouse experimental system. RUNX3 is a strong candidate as a gastric cancer tumor suppressor. The beta subunit gene of PEBP2/CBF is also frequently involved in chromosome rearrangements associated with human leukemia. In this Overview, I will summarize how this growing field has been formed and what are the challenging new frontiers for better understanding of the oncogenic potential of this gene family.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15156173     DOI: 10.1038/sj.onc.1207755

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  110 in total

Review 1.  RUNX1-dependent mechanisms in biological control and dysregulation in cancer.

Authors:  Deli Hong; Andrew J Fritz; Jonathan A Gordon; Coralee E Tye; Joseph R Boyd; Kirsten M Tracy; Seth E Frietze; Frances E Carr; Jeffrey A Nickerson; Andre J Van Wijnen; Anthony N Imbalzano; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2018-12-04       Impact factor: 6.384

2.  Childhood acute myeloid leukemia with bone marrow eosinophilia caused by t(16;21)(q24;q22).

Authors:  Nozomu Kawashima; Akira Shimada; Takeshi Taketani; Yasuhide Hayashi; Nao Yoshida; Kimikazu Matsumoto; Yoshiyuki Takahashi; Seiji Kojima; Koji Kato
Journal:  Int J Hematol       Date:  2012-03-09       Impact factor: 2.490

3.  Fragment of intron 5.2 of the human RUNX1 gene important for transcription activation is neither enhancer nor MAR-element.

Authors:  E N Markova; S V Razin; O L Kantidze
Journal:  Dokl Biochem Biophys       Date:  2012-03-15       Impact factor: 0.788

4.  Tumor suppressor function of RUNX3 in breast cancer.

Authors:  Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

5.  Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.

Authors:  Anastasia R Goloudina; Kan Tanoue; Arlette Hammann; Eric Fourmaux; Xavier Le Guezennec; Dmitry V Bulavin; Sharlyn J Mazur; Ettore Appella; Carmen Garrido; Oleg N Demidov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

6.  Runx1 binds positive transcription elongation factor b and represses transcriptional elongation by RNA polymerase II: possible mechanism of CD4 silencing.

Authors:  Huimin Jiang; Fan Zhang; Takeshi Kurosu; B Matija Peterlin
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

7.  Expression levels of the runt-related transcription factor 1 and 3 genes in the development of acute myeloid leukemia.

Authors:  Adrian Krygier; Dagmara Szmajda; Marta Żebrowska; Agnieszka Jeleń; Ewa Balcerczak
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

Review 8.  Helicobacter pylori eradication to prevent gastric cancer: underlying molecular and cellular mechanisms.

Authors:  Shingo Tsuji; Masahiko Tsujii; Hiroaki Murata; Tsutomu Nishida; Masato Komori; Masakazu Yasumaru; Shuji Ishii; Yoshiaki Sasayama; Sunao Kawano; Norio Hayashi
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

9.  LincRNA-uc002yug.2 involves in alternative splicing of RUNX1 and serves as a predictor for esophageal cancer and prognosis.

Authors:  H Wu; J Zheng; J Deng; L Zhang; N Li; W Li; F Li; J Lu; Y Zhou
Journal:  Oncogene       Date:  2014-12-08       Impact factor: 9.867

10.  Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival.

Authors:  S Wotton; A Terry; A Kilbey; A Jenkins; P Herzyk; E Cameron; J C Neil
Journal:  Oncogene       Date:  2008-06-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.